• AZD2461: Novel PARP Inhibitor Empowering Breast Cancer Re...

  2026-02-28

  AZD2461 is a next-generation poly (ADP-ribose) polymerase inhibitor that uniquely overcomes Pgp-mediated drug resistance and induces robust cell cycle arrest in breast cancer models. Leveraging advanced workflows and troubleshooting insights, researchers can maximize the impact of AZD2461 from in vitro assays to translational preclinical studies.

• 5-(N,N-dimethyl)-Amiloride (hydrochloride): Selective NHE...

  2026-02-27

  5-(N,N-dimethyl)-Amiloride (hydrochloride) is a potent Na+/H+ exchanger inhibitor, widely used to dissect intracellular pH regulation and sodium ion transport. Data show its high selectivity for NHE1 and protective effects in ischemia-reperfusion models. This article clarifies its molecular action, benchmarks, and translational potential in cardiovascular and endothelial research.

• Olaparib (AZD2281): Next-Generation PARP-1/2 Inhibitor fo...

  2026-02-27

  Explore the molecular mechanisms and innovative research applications of Olaparib (AZD2281), a selective PARP-1/2 inhibitor for BRCA-deficient cancer research. This article uniquely examines localized delivery strategies and the integration of nanotechnology for enhanced targeted therapy.

• Olaparib (AZD2281): Selective PARP Inhibitor for BRCA-Def...

  2026-02-26

  Olaparib (AZD2281) revolutionizes BRCA-deficient cancer research by precisely targeting PARP-mediated DNA repair pathways, enabling advanced DNA damage response and tumor radiosensitization studies. Its robust performance in both in vitro and in vivo models empowers researchers to unravel therapeutic vulnerabilities and optimize targeted therapy protocols. Streamline your cancer research workflows with APExBIO's high-quality Olaparib.

• 5-(N,N-dimethyl)-Amiloride Hydrochloride: Mechanisms, Evi...

  2026-02-26

  5-(N,N-dimethyl)-Amiloride hydrochloride is a potent, selective Na+/H+ exchanger inhibitor used in cardiovascular and pH regulation research. This article synthesizes peer-reviewed data and product benchmarks to clarify its mechanisms, research applications, and key limitations. Its high selectivity for NHE1/2/3 makes it central to studies of intracellular pH, ischemia-reperfusion injury, and endothelial dysfunction.

• Harnessing Olaparib (AZD2281, Ku-0059436): Mechanistic In...

  2026-02-25

  This thought-leadership article explores the mechanistic underpinnings and translational opportunities of Olaparib (AZD2281, Ku-0059436), a potent PARP-1/2 inhibitor, for BRCA-deficient cancer research. Beyond standard product descriptions, it integrates peer-reviewed evidence, highlights innovative delivery strategies, and offers actionable strategic guidance for researchers advancing DNA damage response assays, tumor radiosensitization, and targeted therapy development.

• Influenza Hemagglutinin (HA) Peptide: Advanced Strategies...

  2026-02-25

  Discover how the Influenza Hemagglutinin (HA) Peptide empowers advanced protein-protein interaction and exosome pathway research. This in-depth guide explores unique mechanistic insights, optimized workflows, and cutting-edge applications beyond standard HA tag protocols.

• Rucaparib (AG-014699): Next-Generation PARP Inhibitor for...

  2026-02-24

  Discover how Rucaparib (AG-014699, PF-01367338), a potent PARP1 inhibitor, redefines DNA damage response research through advanced radiosensitization and mechanistic insights into apoptosis. Uncover unique applications in PTEN-deficient and ETS fusion-expressing cancer models.

• BMN 673 (Talazoparib): Reimagining PARP1/2 Inhibition for...

  2026-02-24

  This thought-leadership article offers translational researchers a mechanistic deep dive into BMN 673 (Talazoparib) as a potent, selective PARP1/2 inhibitor, integrating recent landmark insights on PARP-DNA complex trapping and BRCA2-RAD51 dynamics. We contextualize the latest findings, compare BMN 673 to other PARP inhibitors, and provide actionable guidance for maximizing its translational and clinical impact, especially in homologous recombination deficient cancers and small cell lung cancer research.

• Influenza Hemagglutinin (HA) Peptide: Deep-Dive into ESCR...

  2026-02-23

  Explore the Influenza Hemagglutinin (HA) Peptide as an advanced molecular biology peptide tag for protein detection and exosome research. This article uniquely connects HA tag peptide utility with ESCRT-independent exosome biogenesis, offering new experimental insights.

• Rucaparib (AG-014699): Potent PARP1 Inhibitor for DNA Dam...

  2026-02-23

  Rucaparib (AG-014699, PF-01367338) is a highly potent PARP1 inhibitor with a Ki of 1.4 nM, widely used in DNA damage response and cancer biology research. Its selectivity and radiosensitizing effects in PTEN-deficient and ETS fusion-expressing cancer models make it indispensable for precise, high-sensitivity assays.

• AZD2461: Unraveling PARP-1 Inhibition and DNA Repair in B...

  2026-02-22

  Discover how AZD2461, a novel PARP inhibitor, redefines breast cancer research by enabling advanced exploration of DNA repair pathway modulation and overcoming drug resistance. This in-depth analysis offers unique insights into mechanistic studies, translational models, and experimental strategies with AZD2461.

• BMN 673 (Talazoparib): Selective PARP Inhibitor for Cance...

  2026-02-21

  BMN 673 (Talazoparib) stands at the forefront of selective PARP inhibition, delivering unmatched potency and DNA repair targeting for homologous recombination deficient cancers. This article provides rigorous experimental workflows, advanced applications, and actionable troubleshooting to optimize studies with this leading compound from APExBIO.

• Solving Lab Workflow Challenges with Influenza Hemaggluti...

  2026-02-20

  This article delivers scenario-driven guidance for biomedical researchers and lab technicians leveraging the Influenza Hemagglutinin (HA) Peptide (SKU A6004) in protein purification and detection workflows. Drawing on peer-reviewed data and real lab challenges, it demonstrates how high-purity, highly soluble HA tag peptide solutions from APExBIO ensure reproducibility, assay sensitivity, and workflow safety. Discover actionable answers to common experimental dilemmas and vendor selection queries rooted in validated best practices.

• Olaparib (AZD2281): Selective PARP-1/2 Inhibitor for BRCA...

  2026-02-20

  Olaparib (AZD2281, Ku-0059436) is a highly selective PARP-1/2 inhibitor optimized for research in homologous recombination-deficient and BRCA-mutant cancer models. Its potency and specificity enable precise DNA damage response assays and tumor radiosensitization studies, supporting advanced targeted therapy research.

395 records 16/27 page Previous Next First page 上5页 1617181920 下5页 Last page